Compare INBK & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INBK | BDSX |
|---|---|---|
| Founded | 1999 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.0M | 276.2M |
| IPO Year | 2013 | 2020 |
| Metric | INBK | BDSX |
|---|---|---|
| Price | $26.67 | $21.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $30.70 | ★ $39.00 |
| AVG Volume (30 Days) | 29.3K | ★ 90.6K |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | ★ 0.90% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.55 | N/A |
| Revenue | $11,541,000.00 | ★ $88,499,000.00 |
| Revenue This Year | $18.74 | $26.51 |
| Revenue Next Year | $13.11 | $20.25 |
| P/E Ratio | $48.54 | ★ N/A |
| Revenue Growth | ★ 101.84 | 24.08 |
| 52 Week Low | $17.05 | $5.26 |
| 52 Week High | $31.09 | $31.97 |
| Indicator | INBK | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 52.40 | 31.27 |
| Support Level | $25.08 | $19.26 |
| Resistance Level | $27.88 | $24.82 |
| Average True Range (ATR) | 0.70 | 1.58 |
| MACD | 0.13 | -0.46 |
| Stochastic Oscillator | 88.49 | 1.25 |
First Internet Bancorp is a bank holding company. Through its subsidiaries, it provides commercial real estate (CRE) lending, including nationwide single tenant lease financing and commercial and industrial (C&I) lending, including business banking or treasury management services. The company offers its products and services through the internet and does not have any branches. With operations organized into a single segment called the Commercial Banking segment, it also provides retail banking services.
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.